{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:46:13Z","timestamp":1782535573957,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015613","name":"Centre Hospitalier Universitaire de Lille","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015613","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Cardiol Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Atrial fibrillation (AF) and\/or the need for oral anticoagulation (OAC) frequently coexist with stable chronic coronary syndrome (CCS). In this population, clinicians must carefully balance ischemic protection against bleeding risk. This review aims to synthesize available evidence and address whether antiplatelet therapy (APT) should be maintained on top of OAC in this specific subset.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Recent trials have provided key evidence. AFIRE, EPIC-CAD, AQUATIC and ADAPT-AF-DES have all demonstrated that OAC monotherapy is not only non-inferior but also superior to combination therapy (OAC plus APT) in terms of net clinical benefit, with fewer major bleeding events and no increase in ischemic complications. The AQUATIC and AFIRE trials even showed an excess in mortality with prolonged combination therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Current evidence supports OAC alone as the preferred long-term antithrombotic strategy in patients with AF and stable CCS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11886-026-02384-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:12:44Z","timestamp":1782533564000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Antithrombotic Management in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation"],"prefix":"10.1007","volume":"28","author":[{"given":"Hubert","family":"Dromas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dany","family":"Janah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basile","family":"Verdier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Schurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"de Saint Nicolas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2917-9273","authenticated-orcid":false,"given":"Gilles","family":"Lemesle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"key":"2384_CR1","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1161\/CIR.0000000000001052","volume":"145","author":"CW Tsao","year":"2022","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Alonso A, Beaton AZ, Bittencourt MS, et al. Heart disease and stroke statistics\u20142022 update: a report from the American Heart Association. Circ Am Heart Assoc. 2022;145:e153-639. https:\/\/doi.org\/10.1161\/CIR.0000000000001052.","journal-title":"Circ Am Heart Assoc"},{"key":"2384_CR2","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1161\/CIR.0000000000001303","volume":"151","author":"SS Martin","year":"2025","unstructured":"Martin SS, Aday AW, Allen NB, Almarzooq ZI, Anderson CAM, Arora P, et al. 2025 heart disease and stroke statistics: a report of US and Global Data From the American Heart Association. Circulation. 2025;151:e41-660. https:\/\/doi.org\/10.1161\/CIR.0000000000001303.","journal-title":"Circulation"},{"key":"2384_CR3","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes: Developed by the task force for the management of chronic coronary syndromes of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3415\u2013537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177.","journal-title":"Eur Heart J"},{"key":"2384_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39:213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"key":"2384_CR5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes: Developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"key":"2384_CR6","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","volume":"148","author":"SS Virani","year":"2023","unstructured":"Virani SS, Newby LK, Arnold SV, Bittner V, Brewer LC, Demeter SH, et al. 2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines. Circ Am Heart Assoc. 2023;148:e9-119. https:\/\/doi.org\/10.1161\/CIR.0000000000001168.","journal-title":"Circ Am Heart Assoc"},{"key":"2384_CR7","doi-asserted-by":"publisher","unstructured":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849\u201160. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"2384_CR8","first-page":"271","volume":"58","author":"G Schurtz","year":"2016","unstructured":"Schurtz G, Bauters C, Ducrocq G, Lamblin N, Lemesle G. Effect of aspirin in addition to oral anticoagulants in stable coronary artery disease outpatients with an indication for anticoagulation. Panminerva Med. 2016;58:271\u201385.","journal-title":"Panminerva Med"},{"key":"2384_CR9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.ijcard.2013.11.030","volume":"170","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Bhatt DL, Steg PG, Gersh BJ, Alberts MJ, Hoffman EB, et al. Long-term cardiovascular outcomes in patients with atrial fibrillation and atherothrombosis in the REACH Registry. Int J Cardiol. 2014;170:413\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2013.11.030.","journal-title":"Int J Cardiol"},{"key":"2384_CR10","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","volume":"64","author":"M Hamon","year":"2014","unstructured":"Hamon M, Lemesle G, Tricot O, Meurice T, Deneve M, Dujardin X, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. JACC Am Coll Cardiol Found. 2014;64:1430\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2014.07.957.","journal-title":"JACC Am Coll Cardiol Found"},{"key":"2384_CR11","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","volume":"381","author":"S Yasuda","year":"2019","unstructured":"Yasuda S, Kaikita K, Akao M, Ako J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381:1103\u201313. https:\/\/doi.org\/10.1056\/NEJMoa1904143.","journal-title":"N Engl J Med"},{"key":"2384_CR12","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","volume":"139","author":"Y Matsumura-Nakano","year":"2019","unstructured":"Matsumura-Nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation American Heart Association. 2019;139:604\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.036768.","journal-title":"Circulation American Heart Association"},{"key":"2384_CR13","doi-asserted-by":"publisher","first-page":"e200107","DOI":"10.1001\/jamanetworkopen.2020.0107","volume":"3","author":"KAA Fox","year":"2020","unstructured":"Fox KAA, Velentgas P, Camm AJ, Bassand J-P, Fitzmaurice DA, Gersh BJ, et al. Outcomes associated with oral anticoagulants plus antiplatelets in patients with newly diagnosed atrial fibrillation. JAMA Netw Open. 2020;3:e200107. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.0107.","journal-title":"JAMA Netw Open"},{"key":"2384_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.ijcard.2015.11.090","volume":"203","author":"Y Ancedy","year":"2016","unstructured":"Ancedy Y, Lecoq C, Saint Etienne C, Ivanes F, Angoulvant D, Babuty D, et al. Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: what is the impact of guideline adherence? Int J Cardiol. 2016;203:987\u201394. https:\/\/doi.org\/10.1016\/j.ijcard.2015.11.090.","journal-title":"Int J Cardiol"},{"key":"2384_CR15","doi-asserted-by":"publisher","first-page":"e0125164","DOI":"10.1371\/journal.pone.0125164","volume":"10","author":"L Fauchier","year":"2015","unstructured":"Fauchier L, Greenlaw N, Ferrari R, Ford I, Fox KM, Tardif J-C, et al. Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY Registry. PLoS ONE. 2015;10:e0125164. https:\/\/doi.org\/10.1371\/journal.pone.0125164.","journal-title":"PLoS ONE"},{"key":"2384_CR16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0049-3848(03)00297-4","volume":"110","author":"F H\u00e9loire","year":"2003","unstructured":"H\u00e9loire F, Weill B, Weber S, Batteux F. Aggregates of endothelial microparticles and platelets circulate in peripheral blood. Variations during stable coronary disease and acute myocardial infarction. Thromb Res. 2003;110:173\u201380. https:\/\/doi.org\/10.1016\/S0049-3848(03)00297-4.","journal-title":"Thromb Res"},{"key":"2384_CR17","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1160\/TH14-12-1007","volume":"114","author":"SB Larsen","year":"2015","unstructured":"Larsen SB, Grove EL, W\u00fcrtz M, Neergaard-Petersen S, Hvas A-M, Kristensen SD. The influence of low-grade inflammation on platelets in patients with stable coronary artery disease. Thromb Haemost. 2015;114:519\u201329. https:\/\/doi.org\/10.1160\/TH14-12-1007.","journal-title":"Thromb Haemost"},{"key":"2384_CR18","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","volume":"340","author":"S Juul-Moller","year":"1992","unstructured":"Juul-Moller S, Edvardsson N, Sorensen S, Jahnmatz B, Ros\u00e9n A, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet. 1992;340:1421\u20135. https:\/\/doi.org\/10.1016\/0140-6736(92)92619-Q.","journal-title":"Lancet"},{"key":"2384_CR19","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/S0140-6736(21)01063-1","volume":"397","author":"B-K Koo","year":"2021","unstructured":"Koo B-K, Kang J, Park KW, Rhee T-M, Yang H-M, Won K-B, et al. Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM): an investigator-initiated, prospective, randomised, open-label, multicentre trial. Lancet. 2021;397:2487\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(21)01063-1.","journal-title":"Lancet"},{"key":"2384_CR20","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/S0140-6736(20)30315-9","volume":"395","author":"M Chiarito","year":"2020","unstructured":"Chiarito M, Sanz-S\u00e1nchez J, Cannata F, Cao D, Sturla M, Panico C, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. The Lancet. 2020;395:1487\u201395. https:\/\/doi.org\/10.1016\/S0140-6736(20)30315-9.","journal-title":"The Lancet"},{"key":"2384_CR21","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","volume":"371","author":"L Mauri","year":"2014","unstructured":"Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, et al. Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-eluting Stents. N Engl J Med. 2014;371:2155\u201366. https:\/\/doi.org\/10.1056\/NEJMoa1409312.","journal-title":"N Engl J Med"},{"key":"2384_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","volume":"385","author":"M Valgimigli","year":"2021","unstructured":"Valgimigli M, Frigoli E, Heg D, Tijssen J, J\u00fcni P, Vranckx P, et al. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med. 2021;385:1643\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2108749.","journal-title":"N Engl J Med"},{"key":"2384_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0140-6736(09)60040-4","volume":"373","author":"T Watson","year":"2009","unstructured":"Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow\u2019s triad revisited. Lancet. 2009;373:155\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(09)60040-4.","journal-title":"Lancet"},{"key":"2384_CR24","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","volume":"167","author":"A Banerjee","year":"2013","unstructured":"Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GYH, et al. Pattern of atrial fibrillation and risk of outcomes: The Loire Valley Atrial Fibrillation Project. Int J Cardiol. 2013;167:2682\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2012.06.118.","journal-title":"Int J Cardiol"},{"key":"2384_CR25","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","volume":"45","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45:3314\u2013414. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176.","journal-title":"Eur Heart J"},{"key":"2384_CR26","doi-asserted-by":"publisher","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","volume":"146","author":"RG Hart","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857\u201367. https:\/\/doi.org\/10.7326\/0003-4819-146-12-200706190-00007.","journal-title":"Ann Intern Med"},{"key":"2384_CR27","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022;145:242\u201355. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.056355.","journal-title":"Circulation"},{"key":"2384_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1160\/TH13-04-0351","volume":"110","author":"A Bernard","year":"2013","unstructured":"Bernard A, Fauchier L, Pellegrin C, Clementy N, Saint Etienne C, Banerjee A, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost. 2013;110:560\u20138. https:\/\/doi.org\/10.1160\/TH13-04-0351.","journal-title":"Thromb Haemost"},{"key":"2384_CR29","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1093\/europace\/eut373","volume":"16","author":"GYH Lip","year":"2014","unstructured":"Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) pilot general registry. Europace. 2014;16:308\u201319. https:\/\/doi.org\/10.1093\/europace\/eut373.","journal-title":"Europace"},{"key":"2384_CR30","doi-asserted-by":"publisher","first-page":"e24964","DOI":"10.1371\/journal.pone.0024964","volume":"6","author":"S Kralev","year":"2011","unstructured":"Kralev S, Schneider K, Lang S, S\u00fcselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS ONE. 2011;6:e24964. https:\/\/doi.org\/10.1371\/journal.pone.0024964.","journal-title":"PLoS ONE"},{"key":"2384_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1001\/jama.1994.03510350050036","volume":"271","author":"EJ Benjamin","year":"1994","unstructured":"Benjamin EJ, Levy D, Vaziri SM, D\u2019Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: The Framingham Heart Study. JAMA. 1994;271:840\u20134. https:\/\/doi.org\/10.1001\/jama.1994.03510350050036.","journal-title":"JAMA"},{"key":"2384_CR32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1093\/eurheartj\/ehad556","volume":"45","author":"A Gautier","year":"2023","unstructured":"Gautier A, Picard F, Ducrocq G, Elbez Y, Fox KM, Ferrari R, et al. New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry. Eur Heart J. 2023;45:366\u201375. https:\/\/doi.org\/10.1093\/eurheartj\/ehad556.","journal-title":"Eur Heart J"},{"key":"2384_CR33","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1161\/CIRCULATIONAHA.123.067938","volume":"149","author":"G Lemesle","year":"2024","unstructured":"Lemesle G, Lamblin N, Schurtz G, Labreuche J, Duhamel A, Verdier B, et al. Comparison of incidence and prognostic impact of ischemic, major bleeding and heart failure events in patients with chronic coronary syndrome: insights from the CORONOR registry. Circulation. 2024;149:1708\u201316. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067938.","journal-title":"Circulation"},{"key":"2384_CR34","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.jacc.2014.01.069","volume":"63","author":"WJ Kikkert","year":"2014","unstructured":"Kikkert WJ, van Geloven N, van der Laan MH, Vis MM, Baan J, Koch KT, et al. The prognostic value of Bleeding Academic Research Consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2014;63:1866\u201375. https:\/\/doi.org\/10.1016\/j.jacc.2014.01.069.","journal-title":"J Am Coll Cardiol"},{"key":"2384_CR35","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.jacc.2005.09.060","volume":"47","author":"SV Rao","year":"2006","unstructured":"Rao SV, O\u2019Grady K, Pieper KS, Granger CB, Newby LK, Mahaffey KW, et al. A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes. J Am Coll Cardiol. 2006;47:809\u201316. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.060.","journal-title":"J Am Coll Cardiol"},{"key":"2384_CR36","unstructured":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology | European Heart Journal | Oxford Academic [Internet]. [cit\u00e9 29 avr 2025]. https:\/\/academic-oup-com.ressources-electroniques.univ-lille.fr\/eurheartj\/article\/32\/15\/1854\/566964?login=true. Consult\u00e9 le 29 avr 2025"},{"key":"2384_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jcin.2010.10.011","volume":"4","author":"FWA Verheugt","year":"2011","unstructured":"Verheugt FWA, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011;4:191\u20137. https:\/\/doi.org\/10.1016\/j.jcin.2010.10.011.","journal-title":"JACC Cardiovasc Interv"},{"key":"2384_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.4244\/eijv3i3a71","volume":"3","author":"M Hamon","year":"2007","unstructured":"Hamon M, Filippi-Codaccioni E, Riddell JW, Lepage O. Prognostic impact of major bleeding in patients with acute coronary syndromes. A systematic review and meta-analysis. EuroIntervention. 2007;3:400\u20138. https:\/\/doi.org\/10.4244\/eijv3i3a71.","journal-title":"EuroIntervention"},{"key":"2384_CR39","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1161\/01.CIR.0000162477.70955.5F","volume":"111","author":"MS Sabatine","year":"2005","unstructured":"Sabatine MS, Morrow DA, Giugliano RP, Burton PBJ, Murphy SA, McCabe CH, et al. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111:2042\u20139. https:\/\/doi.org\/10.1161\/01.CIR.0000162477.70955.5F.","journal-title":"Circulation"},{"key":"2384_CR40","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1016\/j.ehj.2003.09.008","volume":"24","author":"H Reinecke","year":"2003","unstructured":"Reinecke H, Trey T, Wellmann J, Heidrich J, Fobker M, Wichter T. Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J. 2003;24:2142\u201350. https:\/\/doi.org\/10.1016\/j.ehj.2003.09.008.","journal-title":"Eur Heart J"},{"key":"2384_CR41","doi-asserted-by":"publisher","first-page":"5905022","DOI":"10.1155\/2022\/5905022","volume":"2022","author":"D Fukamachi","year":"2022","unstructured":"Fukamachi D, Okumura Y, Matsumoto N, Tachibana E, Oiwa K, Ichikawa M, et al. Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease. J Interv Cardiol. 2022;2022:5905022. https:\/\/doi.org\/10.1155\/2022\/5905022.","journal-title":"J Interv Cardiol"},{"key":"2384_CR42","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa2407362","volume":"391","author":"MS Cho","year":"2024","unstructured":"Cho MS, Kang D-Y, Ahn J-M, Yun S-C, Oh Y-S, Lee CH, et al. Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease. N Engl J Med. 2024;391:2075\u201386. https:\/\/doi.org\/10.1056\/NEJMoa2407362.","journal-title":"N Engl J Med"},{"key":"2384_CR43","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJMoa2507532","volume":"393","author":"G Lemesle","year":"2025","unstructured":"Lemesle G, Didier R, Steg PG, Simon T, Montalescot G, Danchin N, et al. Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N Engl J Med. 2025;393:1578\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2507532.","journal-title":"N Engl J Med"},{"key":"2384_CR44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2512091","author":"S-J Lee","year":"2026","unstructured":"Lee S-J, Yu HT, Lee Y-J, Lee S-H, Heo JH, Ahn SG, et al. Therapy for atrial fibrillation in patients with drug-eluting stents. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/NEJMoa2512091.","journal-title":"N Engl J Med"},{"key":"2384_CR45","doi-asserted-by":"publisher","first-page":"JC15","DOI":"10.7326\/ANNALS-25-05478-JC","volume":"179","author":"D Mukherjee","year":"2026","unstructured":"Mukherjee D, ACP Journal Club Editorial Team at McMaster University. In AF with drug-eluting stent for \u22651 y, NOACs were noninferior to NOAC + clopidogrel for a composite of adverse clinical events at 1 y. Ann Intern Med. 2026;179:JC15. https:\/\/doi.org\/10.7326\/ANNALS-25-05478-JC.","journal-title":"Ann Intern Med"},{"key":"2384_CR46","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1161\/CIRCULATIONAHA.125.077141","volume":"153","author":"G Lemesle","year":"2026","unstructured":"Lemesle G, Didier R, Diallo A, Dromas H, Bauters C, Steg PG, et al. Anticoagulation and antiplatelet therapy versus anticoagulation alone in patients with chronic coronary syndrome receiving long-term anticoagulation: a meta-analysis of randomized clinical trials. Circulation. 2026;153:294\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.077141.","journal-title":"Circulation"},{"key":"2384_CR47","doi-asserted-by":"publisher","first-page":"103250","DOI":"10.1016\/j.cpcardiol.2025.103250","volume":"51","author":"F Garagoli","year":"2026","unstructured":"Garagoli F, Masson W, Lobo M, Barbagelata L, Cayla G, Gilard M, et al. Antiplatelet therapy in patients with chronic coronary syndrome requiring oral anticoagulation: an updated meta-analysis of randomized trials. Curr Probl Cardiol. 2026;51:103250. https:\/\/doi.org\/10.1016\/j.cpcardiol.2025.103250.","journal-title":"Curr Probl Cardiol"},{"key":"2384_CR48","unstructured":"Bayer. A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA [Internet]. clinicaltrials.gov; 2025 nov. Report No.: NCT05686070. https:\/\/clinicaltrials.gov\/study\/NCT05686070. Consult\u00e9 le 25 janv 2026"},{"key":"2384_CR49","unstructured":"Janssen Research & Development, LLC. A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation [Internet]. clinicaltrials.gov; 2026 janv. Report No.: NCT05757869. https:\/\/clinicaltrials.gov\/study\/NCT05757869. Consult\u00e9 le 25 janv 2026"},{"key":"2384_CR50","unstructured":"Insel Gruppe AG, University Hospital Bern. Monotherapy With a P2Y12 Inhibitor Followed by a Direct-acting Oral Anticoagulant in Patients With ATRial fIbrillation Undergoing suprafleX Cruz Coronary Stent Implantation [Internet]. clinicaltrials.gov; 2024 oct. Report No.: NCT05955365. https:\/\/clinicaltrials.gov\/study\/NCT05955365. Consult\u00e9 le 25 janv 2026"}],"container-title":["Current Cardiology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11886-026-02384-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11886-026-02384-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:12:49Z","timestamp":1782533569000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11886-026-02384-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2384"],"URL":"https:\/\/doi.org\/10.1007\/s11886-026-02384-2","relation":{},"ISSN":["1534-3170"],"issn-type":[{"value":"1534-3170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All reported studies with human subjects performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, national research committee standards, and international guidelines).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"63"}}